Novel ionizable lipids and lipid nanoparticle compositions using the lipids
The lipid nanoparticle system prepared by novel ionizable lipid compounds solves the problems of unstable efficacy and large side effects of existing lipid nanoparticles in gene delivery, and realizes efficient and stable gene delivery and vaccine development, which is suitable for gene therapy and mRNA vaccines.
Patent Information
- Application Number
- CN202580027919.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2025-02-18
- Filing Date
- 2025-02-19
- Publication Date
- 2026-11-17
AI Technical Summary
Existing lipid nanoparticles suffer from problems such as unstable gene delivery efficiency, poor targeting, significant side effects, inconvenient storage and distribution, and high cost during gene delivery. In particular, gene delivery efficiency decreases with repeated administration, failing to meet the needs of gene therapy and mRNA vaccines.
Develop a novel ionizable lipid compound for the preparation of lipid nanoparticles. By optimizing the lipid composition and structure, improve gene encapsulation efficiency and in vivo gene delivery efficiency. The compound is selected from combinations of ionizable lipids, phospholipids, cholesterol and PEG lipids with specific structures to form a stable lipid nanoparticle system.
It achieves excellent gene delivery efficacy even with repeated administration, improves the delivery efficiency of gene therapy and mRNA vaccines, reduces side effects and enhances the convenience of storage and distribution, and is applicable to the development of vaccines for a variety of rare diseases and cancers.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] This disclosure relates to novel ionizable lipids, lipid nanoparticle compositions using the lipids, and their uses. Background Technology
[0002] Nucleic acid-based drugs are used not only as therapeutics but also as preventative agents, which are administered via injection of genes that express antigens for specific diseases. Gene-based vaccines are classified into DNA vaccines, RNA vaccines, and viral vector vaccines; among them, RNA vaccines involve injecting mRNA encoding an antigen into the human body to express the antigen and induce antibody formation. Therefore, they offer advantages such as eliminating concerns about the potential risks of infection caused by viral vector vaccines or gene mutations caused by DNA vaccines, and enabling rapid development. Consequently, RNA vaccines have attracted attention as an effective countermeasure against the COVID-19 outbreak in 2019.
[0003] However, because genes are large molecules that are easily degraded by nucleases in the human body and carry negative charges, they are not easily delivered into cells, necessitating stable and efficient methods for delivering genes to desired sites. As gene delivery systems, delivery technologies based on various materials have been reported, such as lipids, polymers, dendritic macromolecules, and inorganic metals. Among these, lipid nanoparticles, as lipid carriers, have gained recognition as a clinically useful delivery system for nucleic acid drugs (such as siRNA and mRNA) following their application not only in the development of the first siRNA drug, patisiran (ONPATTRO®), approved by the FDA in 2018, but also in the development of a COVID-19 mRNA vaccine approved for emergency use in 2020.
[0004] Currently, lipid nanoparticles are typically used in a predetermined mixture of four components: ionizable lipids, phospholipids (co-lipids), cholesterol (structure-maintaining lipids), and PEGylated lipids. However, with the comprehensive development of gene therapies for various indications, there are still unmet needs in various aspects of lipid nanoparticle-based delivery vectors, including improving gene delivery efficiency, maintaining gene delivery efficiency in specific diseases (such as liver disease), improving stability, enhancing targeting properties, ensuring ease of storage and delivery, reducing side effects, lowering costs, and addressing breakthrough infections. Therefore, there is an ongoing need to develop lipid nanoparticles using novel ionizable lipid delivery vectors.
[0005] Systemic administration of lipid nanoparticles can be used for gene therapy development, but most lipid nanoparticles suffer from the following problem: when repeatedly administered to maintain therapeutic efficacy, gene delivery efficiency cannot be maintained and even decreases, thus necessitating the development of novel ionizable lipid transporters to compensate for this. Local administration of lipid nanoparticles can be used for the development of mRNA vaccines or local therapies, and in this case, unnecessary systemic exposure of lipid nanoparticles may cause side effects, thus requiring the development of ionizable lipid transporters with high protein expression rates at local sites.
[0006] With the future entry of gene therapy into the pharmaceutical market and its continued market expansion, it is hoped that by obtaining various ionizable lipids different from existing ionizable lipids and by developing novel lipid nanoparticle systems that utilize them, gene therapies for a variety of rare diseases, various mRNA vaccines, and cancer vaccines can be developed, thereby further improving gene delivery efficiency and addressing unmet needs when administered systemically or repeatedly. Summary of the Invention
[0007] Technical issues
[0008] One object of this disclosure is to provide novel ionizable lipid compounds.
[0009] Another object of this disclosure is to provide lipid nanoparticles using the ionizable lipid compound.
[0010] Another objective of this disclosure is to provide the pharmaceutical uses of the lipid nanoparticles.
[0011] Technical solution
[0012] To achieve the above objectives, this disclosure provides a compound selected from compounds represented by Formula 1, pharmaceutically acceptable salts thereof, tautomers thereof, prodrugs thereof, or stereoisomers thereof, wherein R 1 R 2 R 3 and (R) 4 )-X coordinates around the central carbon:
[0013] <Formula 1>
[0014]
[0015] In Equation 1 above, R 1 R 2 and R 3Each group is independently selected from branched or straight-chain C6-C30 alkyl, alkenyl, alkynyl, C6-C30 cycloalkyl, aryl, or heteroaryl groups, wherein at one or more carbon positions, three or more carbons away from the central carbon, one or more -CH2- groups are replaced by any one of the following groups: -O-, -CH(OH)-, -C(=O)-, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -OP(=O)(OR 5 )O-, -OC(=S)-, -C(=S)O-, -SC(=O)-, -C(=O)S-, -SC(=S)-, -C(=S)S-, -SC(=O)O-, -SC(=S)O-, -OC(=O)S-, -OC(=S)O-, -S-, -SS-, -NR 5 -、-C(=O)NR 5 -、-NR 5 C(=O)-、-OC(=O)NR 5 -、-NR 5 C(=O)O-、-C(=S)NR 5 -、-NR 5 C(=S)-、-OC(=S)NR 5 -、-NR 5 C(=S)O-、-SC(=O)NR 5 -、-SC(=S)NR 5 -and-NR 5 C(=O)S-, where each R 5 Independently selected from hydrogen, C1-C20 alkyl, C2-C20 alkenyl, alkynyl, C3-C20 cycloalkyl, aryl, or heteroaryl; R 4 Selected from branched or straight-chain C2-C12 alkylene, alkenylene, ynylene, (C6-C12)cycloalkylene, arylene, or heteroarylene; wherein one or more -CH2- groups are substituted or not substituted from any one of the following groups: -O-, -CH(OH)-, -C(=O)-, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -OP(=O)(OR 5 )O-, -OC(=S)-, -C(=S)O-, -SC(=O)-, -C(=O)S-, -SC(=S)-, -C(=S)S-, -SC(=O)O-, -SC(=S)O-, -OC(=O)S-, -OC(=S)O-, -S-, -SS-, -NR 5 -、-C(=O)NR 5 -、-NR 5 C(=O)-、-OC(=O)NR 5 -、-NR5 C(=O)O-、-C(=S)NR 5 -、-NR 5 C(=S)-、-OC(=S)NR 5 -、-NR 5 C(=S)O-、-SC(=O)NR 5 -、-SC(=S)NR 5 -and-NR 5 C(=O)S-; X is selected from hydrogen or a chain or cyclic heterogroup containing an ionizable amine, wherein the cyclic heterogroup is substituted with or unsubstituted by a C1-C6 alkyl, hydroxyl, or hydroxyC1-C6 alkyl group; and n can be selected from 0 or 1.
[0016] This disclosure provides a lipid nanoparticle composition comprising the compound.
[0017] Furthermore, this disclosure provides a composition for drug delivery comprising the lipid nanoparticle composition.
[0018] Beneficial effects
[0019] Lipid nanoparticles containing novel ionizable lipids according to this disclosure have been shown to exhibit excellent gene encapsulation efficiency and in vivo gene delivery efficiency, and also exhibit excellent gene delivery efficacy even with repeated administration, thus making them effective for the development of gene therapies for various indications. Detailed Implementation
[0020] This disclosure will be described in detail below.
[0021] This disclosure provides a compound selected from compounds represented by Formula 1, pharmaceutically acceptable salts thereof, tautomers thereof, prodrugs thereof, or stereoisomers thereof, wherein R 1 R 2 R 3 and (R) 4 )-X coordinates around the central carbon:
[0022] <Formula 1>
[0023]
[0024] In Equation 1 above, R 1 R 2 and R 3Each of these groups can be independently selected from branched or straight-chain C6-C30 alkyl, alkenyl, alkynyl, C6-C30 cycloalkyl, aryl, or heteroaryl groups, wherein at one or more carbon positions, three or more carbons away from the central carbon, one or more -CH2- groups can be replaced by any one of the following groups: -O-, -CH(OH)-, -C(=O)-, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -OP(=O)(OR 5 )O-, -OC(=S)-, -C(=S)O-, -SC(=O)-, -C(=O)S-, -SC(=S)-, -C(=S)S-, -SC(=O)O-, -SC(=S)O-, -OC(=O)S-, -OC(=S)O-, -S-, -SS-, -NR 5 -、-C(=O)NR 5 -、-NR 5 C(=O)-、-OC(=O)NR 5 -、-NR 5 C(=O)O-、-C(=S)NR 5 -、-NR 5 C(=S)-、-OC(=S)NR 5 -、-NR 5 C(=S)O-、-SC(=O)NR 5 -、-SC(=S)NR 5 -and-NR 5 C(=O)S-, where each R 5 It can be independently selected from hydrogen, C1-C20 alkyl, C2-C20 alkenyl, alkynyl, C3-C20 cycloalkyl, aryl or heteroaryl.
[0025] In Equation 1 above, R 4 The group can be selected from branched or straight-chain C2-C12 alkylene, alkenylene, ynylene, (C6-C12)cycloalkylene, arylene, or heteroarylene groups; wherein one or more -CH2- groups may be substituted or not substituted from any one of the following groups: -O-, -CH(OH)-, -C(=O)-, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -OP(=O)(OR 5 )O-, -OC(=S)-, -C(=S)O-, -SC(=O)-, -C(=O)S-, -SC(=S)-, -C(=S)S-, -SC(=O)O-, -SC(=S)O-, -OC(=O)S-, -OC(=S)O-, -S-, -SS-, -NR 5 -、-C(=O)NR 5 -、-NR 5C(=O)-、-OC(=O)NR 5 -、-NR 5 C(=O)O-、-C(=S)NR 5 -、-NR 5 C(=S)-、-OC(=S)NR 5 -、-NR 5 C(=S)O-、-SC(=O)NR 5 -、-SC(=S)NR 5 -and-NR 5 C(=O)S-; X may be selected from hydrogen or a chain or cyclic heterogroup containing an ionizable amine, wherein the cyclic heterogroup may be substituted with or not substituted with C1-C6 alkyl, hydroxyl or hydroxyC1-C6 alkyl; and n may be selected from 0 or 1.
[0026] Preferably, R 1 R 2 and R 3 Each can be independently represented by the following equation 1-A:
[0027] <Formula 1-A>
[0028]
[0029] In Formula 1-A above, L can be a (C2-C5) alkylene group; A can be selected from the group consisting of: -O-, -C(=O)-, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -OC(=S)-, -C(=S)O-, -SC(=O-, -C(=O)S-, -SC(=S-, -C(=S)S-, -SC(=O)O-, -OC(=O)S-, -S-, -SS-, -C(=O)NR 5 -、-OC(=O)NR 5 -、-C(=S)NR 5 - and -OC(=S)NR 5 - and R can be selected from branched or straight-chain C4-C25 alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heteroaryl, wherein one or more of its -CH2- groups may be substituted or not substituted from any one of the group consisting of -O-, -S- and -SS-, but this disclosure is not limited thereto.
[0030] For example, Formula 1-A corresponding to the lipid tail can be selected from the following structural formulas 1 to 3, or a combination thereof, but this disclosure is not limited thereto.
[0031] <Structure 1>
[0032]
[0033] <Structure 2>
[0034]
[0035] <Structure 3>
[0036]
[0037] In Equation 1 above, R 4 The -CH2- group can be selected from C2-C6 alkylene, alkenylene, or ynylene groups, wherein one or more of the -CH2- groups may be substituted or not substituted from any of the following group: -NR 5 -、-C(=O)NR 5 -、-OC(=O)NR 5 -、-C(=S)NR 5 -、-OC(=S)NR 5 -、-SC(=O)NR 5 - and -SC(=S)NR 5 -, where each R 5 It may be independently selected from hydrogen or C1-C6 alkyl, but this disclosure is not limited thereto.
[0038] In Formula 1 above, X may be selected from an amino group substituted with one or more C1-C4 alkyl groups; or a cyclic heterogroup selected from the group consisting of piperidine, piperazine and imidazole, wherein the cyclic heterogroup may be substituted with C1-C4 alkyl, hydroxy or hydroxyC1-C4 alkyl or not substituted, but this disclosure is not limited thereto.
[0039] For example, X and R, corresponding to the polar head structure and represented by the following equation 1-B 4 The structure may be selected from the following structural formulas 4 or 5, or a combination thereof, but this disclosure is not limited thereto.
[0040] <Formula 1-B>
[0041]
[0042] <Structure 4>
[0043]
[0044] <Structure 5>
[0045]
[0046] More preferably, this disclosure may include compounds represented by the following formula:
[0047] <Formula 1-1>
[0048]
[0049] Compound 1: Di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(3-(piperidin-1-yl)propamido)pimercate, molecular formula: C 48 H 84 N₂O₇, molecular weight: 801.21
[0050] <Equation 1-2>
[0051]
[0052] Compound 2: Di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(5-(dimethylamino)pentamido)pimelic acid ester, molecular formula: C 47 H 84 N₂O₇, molecular weight: 789.20
[0053] <Formula 1-3>
[0054]
[0055] Compound 3: Di((Z)-dodecano-5-en-1-yl)4-(((4-(dimethylamino)butoxy)carbonyl)amino)-4-(3-oxo-3-(((Z)-tetrate-6-en-1-yl)oxy)propyl)heptanedioate, molecular formula: C 54 H 98 N₂O₈, molecular weight: 903.38
[0056] <Equation 1-4>
[0057]
[0058] Compound 4: Di((Z)-dodec-5-en-1-yl)4-(3-(((Z)-dodec-5-en-1-yl)oxy)-3-oxopropyl)-4-(3-(piperidin-1-yl)propamido)pimercate, molecular formula: C 54 H 96 N₂O₇, molecular weight: 885.37
[0059] <Formula 1-5>
[0060]
[0061] Compound 5: Di((Z)-tetradec-9-en-1-yl)4-(3-oxo-3-(((Z)-tetradec-9-en-1-yl)oxy)propyl)-4-(3-(piperidin-1-yl)propamido)pimercate, molecular formula: C 60 H 108 N₂O₇, molecular weight: 969.53
[0062] <Formula 1-6>
[0063]
[0064] Compound 6: Di((Z)-oct-3-en-1-yl)4-(3-(((Z)-oct-3-en-1-yl)oxy)-3-oxopropyl)-4-(3-(piperidin-1-yl)propamido)pimercate, molecular formula: C 42 H 72 N₂O₇, molecular weight: 717.05
[0065] <Formula 1-7>
[0066]
[0067] Compound 7: Di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(1-methylpiperidin-4-carboxamido)pimercate, molecular formula: C 47 H 82 N₂O₇, molecular weight: 787.18
[0068] <Formula 1-8>
[0069]
[0070] Compound 8: Di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(1-methylpiperidin-3-carboxamido)pimercate, molecular formula: C 47 H 82 N₂O₇, molecular weight: 787.18
[0071] <Equation 1-9>
[0072]
[0073] Compound 9: Bis(2-(heptylthio)ethyl)4-(3-(2-(heptylthio)ethoxy)-3-oxopropyl)-4-(3-(piperidin-1-yl)propamido)pimercate, molecular formula: C 45 H 84N2O7S3, molecular weight: 861.35
[0074] <Formula 1-10>
[0075]
[0076] Compound 10: Di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(1-(2-hydroxyethyl)piperidin-4-carboxamido)pimercate, molecular formula: C 48 H 84 N₂O₈, molecular weight: 817.21
[0077] <Formula 1-11>
[0078]
[0079] Compound 11: Di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(4-(piperidin-1-yl)butamido)pimercate, molecular formula: C 49 H 86 N₂O₇, molecular weight: 815.23
[0080] <Equation 1-12>
[0081]
[0082] Compound 12: 4-(3-(piperidin-1-yl)propamido)-4-(3-(((Z)-tetradec-9-enoyl)oxy)propyl)heptane-1,7-diyl(9Z,9'Z)-bis(tetradec-9-enolate), molecular formula: C 60 H 108 N₂O₇, molecular weight: 969.53
[0083] <Formula 1-13>
[0084]
[0085] Compound 13: Di((Z)-dec-4-en-1-yl)4-(3-(1H-imidazol-1-yl)propamido)-4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)pimercate, molecular formula: C 46 H 77 N3O7, molecular weight: 784.14
[0086] <Formula 1-14>
[0087]
[0088] Compound 14: bis(3-hexylundecyl)4-(3-((3-hexylundecyl)oxy)-3-oxopropyl)-4-(3-(piperidin-1-yl)propamido)pimercate, molecular formula: C 69 H 132 N₂O₇, molecular weight: 1101.82
[0089] <Formula 1-15>
[0090]
[0091] Compound 15: bis(3-hexylundecyl)4-(3-oxo-3-(undecyloxy)propyl)-4-(3-(piperidin-1-yl)propamido)pimercate, molecular formula: C 63 H 120 N₂O₇, molecular weight: 1017.66
[0092] <Formula 1-16>
[0093]
[0094] Compound 16: bis(3-hexylundecyl)4-(((3-(dimethylamino)propoxy)carbonyl)amino)-4-(3-(((3-hexylundecyl)oxy)-3-oxopropyl)pimercate, molecular formula: C 67 H 130 N₂O₈, molecular weight: 1091.78
[0095] <Formula 1-17>
[0096]
[0097] Compound 17: bis(3-hexylundecyl)4-(((3-(diethylamino)propoxy)carbonyl)amino)-4-(3-(((3-hexylundecyl)oxy)-3-oxopropyl)pimercate, molecular formula: C 69 H 134 N₂O₈, molecular weight: 1119.84
[0098] <Formula 1-18>
[0099]
[0100] Compound 18: bis(3-hexylundecyl)4-(3-((3-hexylundecyl)oxy)-3-oxopropyl)-4-(1-(2-hydroxyethyl)piperidin-4-carboxamido)pimercate, molecular formula: C 69 H 132N₂O₈, molecular weight: 1117.82
[0101] <Formula 1-19>
[0102]
[0103] Compound 19: 4-(3-((2-hexyldecanoyl)oxy)propyl)-4-(3-(piperidin-1-yl)propamido)heptane-1,7-dimethylbis(2-hexyldecanoate), Molecular formula: C 66 H 126 N₂O₇, molecular weight: 1059.74
[0104] <Formula 1-20>
[0105]
[0106] Compound 20: bis(3-hexylundecyl)4-(3-(1H-imidazol-1-yl)propamido)-4-(3-((3-hexylundecyl)oxy)-3-oxopropyl)pimercate, molecular formula: C 67 H 125 N3O7, molecular weight: 1084.75
[0107] <Equation 1-21>
[0108]
[0109] Compound 21: Di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(3-(4-methylpiperazin-1-yl)propamido)pimercate, molecular formula: C 48 H 85 N3O7, molecular weight: 816.22
[0110] <Equation 1-22>
[0111]
[0112] Compound 22: Di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(piperidin-1-yl)heptanedioate, molecular formula: C 45 H 79 NO6, molecular weight: 730.13
[0113] <Formula 1-23>
[0114]
[0115] Compound 23: Di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(4-(hydroxymethyl)piperidin-1-yl)pimercate, molecular formula: C 46 H 81 NO7, molecular weight: 760.15
[0116] <Formula 1-24>
[0117]
[0118] Compound 24: Di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(4-methylpiperazin-1-yl)pimercate, molecular formula: C 45 H 80 N₂O₆, molecular weight: 745.14
[0119] Most preferably, the compound may be one or more selected from the group consisting of: (1) bis((Z)-dec-4-en-1-yl)4-(3-((((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(3-(piperidin-1-yl)propamido)pimelic acid ester, (3) bis((Z)-dodec-5-en-1-yl)4-(((4-(dimethylamino)butoxy)carbonyl)amino)-4-(3-oxo-3-((((Z)-tetrace-6-en-1-yl)oxy) (4) Di((Z)-dodec-5-en-1-yl)4-(3-(((Z)-dodec-5-en-1-yl)oxy)-3-oxopropyl)-4-(3-(piperidin-1-yl)propamido)pimelic acid ester, (5) Di((Z)-tetradec-9-en-1-yl)4-(3-oxo-3-(((Z)-tetradec-9-en-1-yl)oxy)propyl)-4-(3-(piperidin-1-yl)propamido)pimelic acid ester, (6) Di((Z)-oct-3 -en-1-yl)4-(3-(((Z)-oct-3-en-1-yl)oxy)-3-oxopropyl)-4-(3-(piperidin-1-yl)propamido)pimelic acid ester, (7) di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(1-methylpiperidin-4-carboxamido)pimelic acid ester, (8) di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy) (14) bis(3-hexylundecyl)4-(3-((3-hexylundecyl)oxy)-3-oxopropyl)-4-(3-(piperidin-1-yl)propamido)pimelic acid ester, and (18) bis(3-hexylundecyl)4-(3-((3-hexylundecyl)oxy)-3-oxopropyl)-4-(1-(2-hydroxyethyl)piperidin-4-carboxamido)pimelic acid ester, but this disclosure is not limited thereto.
[0120] The compound may include a pharmaceutically acceptable salt form exhibiting the same or similar activity.
[0121] As used herein, "pharmaceutically acceptable" means having a safety and efficacy profile suitable for administration to humans, and being non-toxic to cells or humans exposed to the compound or its salts.
[0122] This salt can be used in any pharmaceutically acceptable form, either a basic or acidic salt. The basic salt can be used in any form, either an organic or inorganic basic salt, and can be selected from the group consisting of: sodium salts, potassium salts, calcium salts, lithium salts, magnesium salts, cesium salts, amine salts, ammonium salts, triethylammonium salts, and pyridinium salts. For the acidic salt, acid addition salts formed from free acids are useful. As a free acid, inorganic or organic acids may be used; examples of inorganic acids may include hydrochloric acid, bromic acid, sulfuric acid, sulfurous acid, phosphoric acid, diphosphoric acid, and nitric acid; and examples of organic acids may include citric acid, acetic acid, maleic acid, malic acid, fumaric acid, gluconic acid, methanesulfonic acid, benzenesulfonic acid, camphorsulfonic acid, oxalic acid, malonic acid, glutaric acid, acetic acid, gluconic acid, succinic acid, tartaric acid, 4-toluenesulfonic acid, galacturonic acid, pyric acid, glutamic acid, citric acid, aspartic acid, and stearic acid, but this disclosure is not limited thereto, and all salts formed using various inorganic and organic acids commonly used in the art may be included.
[0123] Furthermore, the compound may include not only the salts mentioned above, but also all salts, hydrates, solvates, derivatives, etc., that can be prepared by conventional methods. Addition salts can be prepared by conventional methods, and can be prepared by dissolving the compound in a water-soluble organic solvent (e.g., acetone, methanol, ethanol, or acetonitrile), adding an excess organic base or an alkaline aqueous solution of an inorganic base salt, followed by precipitation or crystallization. Alternatively, addition salts can be obtained by evaporating the solvent or excess base from the mixture and then drying the residue, or by filtering the precipitated salt.
[0124] This disclosure provides a lipid nanoparticle composition comprising the compound.
[0125] This compound can function as an ionizable lipid.
[0126] The lipid nanoparticle composition containing this compound exhibits excellent safety and stability and functions as a transporter, enabling genes containing RNA, DNA, or mixtures thereof as active ingredients to fully exert their effects in cells. Therefore, the lipid nanoparticles containing this novel ionizable lipid compound demonstrate excellent gene encapsulation efficiency and in vivo gene delivery efficiency, and are characterized by exhibiting excellent gene delivery function even with repeated administration, thus making them effective as compositions for drug delivery.
[0127] The lipid nanoparticle composition may further comprise one or more lipids selected from the group consisting of neutral lipids, steroids, and polymer-conjugated lipids.
[0128] Neutral lipids may be phospholipids or glycolipids. Specifically, phospholipids may be selected from one or more of the group consisting of: dioleoylphosphatidylethanolamine (DOPE), distearylphosphatidylcholine (DSPC), palmitoyloleoylphosphatidylcholine (POPC), egg yolk phosphatidylcholine (EPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), distearylphosphatidylethanolamine (DSPE), phosphatidylethanolamine (PE), and dipalmitoylphosphatidylethanolamine; and glycolipids may be selected from one or more of the group consisting of: glucosylceramide, galactosylceramide, glucosphosine, galactosphosine, and phosphoglycosylceramide, but this disclosure is not limited thereto.
[0129] Steroids may be one or more selected from the group consisting of cholesterol, bile acid derivatives and bile acid derivatives, but this disclosure is not limited thereto.
[0130] The polymer-conjugated lipid can be a polyethylene glycol-modified lipid having a structure in which a water-soluble polymer is bonded to a lipid, and the polyethylene glycol-modified lipid can be one or more selected from the group consisting of: PEG-DAA bonded to a dialkoxypropyl group; PEG-DAG bonded to a diacylglycerol, including PEG-c-DOMG and PEG-DMG; PEG-PE bonded to a phospholipid (such as phosphatidylethanolamine), including PEG-DLPE, PEG-DMPE and PEG-DSPE; PEG-CER bonded to a ceramide; PEG-DAG bonded to cholesterol or a derivative thereof; PEG-modified phosphatidic acid; PEG-modified dialkylamine; and PEG-modified dialkylglycerol, but this disclosure is not limited thereto. Furthermore, the polyethylene glycol-modified lipid can be a functionalized PEG having a functional group bonded to the side not bonded to the lipid. In this case, the functional group that can be used may be one or more selected from the group consisting of succinyl, carboxylic acid, maleimide, N-hydroxysuccinylimide, amino group, biotin, cyanurate group and folic acid group, but this disclosure is not limited thereto.
[0131] The ionizable lipid can be prepared into lipid nanoparticles, which contain neutral lipids, steroids, polymer-conjugated lipids, etc.
[0132] For compositions suitable for preparing lipid nanoparticles, the lipid nanoparticle composition may contain, in addition to the active ingredient, 20 mol% to 65 mol% of ionizable lipids, 2.5 mol% to 30 mol% of neutral lipids, 20 mol% to 60 mol% of steroids, and 0.5 mol% to 5 mol% of polymer-conjugated lipids. For example, lipids conjugated with ionizable lipids:neutral lipids:steroids:polymers can be formulated in a molar percentage selected from the group consisting of: 60:5:33.5:1.5, 50:10:38.5:1.5, 40:15:43.5:1.5, 30:20:48.5:1.5, 25:25:48.5:1.5, 59.5:5:33.5:2.0, 49.5:10:38.5:2.0, 39.5:15:43.5:2.0, 29.5:20:48.5:2.0, 24.5:25:48.5:2.0, 59:5:33.5:2 .5, 49:10:38.5:2.5, 39:15:43.5:2.5, 29:20:48.5:2.5, 24:25:48.5:2.5, 58.5:5:33.5:3.0, 48.5:10:38.5:3.0, 38.5:15:43.5:3.0, 28.5:20:48.5:3.0, 23.5:25:48.5:3.0, 58:5:33.5:3.5, 48:10:38.5:3.5, 38:15:43.5:3.5, 28:20:48.5:3.5, and 23:25:48.5:3.5.
[0133] The lipid nanoparticle composition may further contain preventative or therapeutic agents.
[0134] The agent may be a gene comprising single-stranded or double-stranded RNA, DNA, or a mixture thereof, and specifically, may be one or more selected from the group consisting of: small interfering RNA (siRNA), ribosomal RNA (rRNA), ribonucleic acid (RNA), deoxyribonucleic acid (DNA), complementary deoxyribonucleic acid (cDNA), aptamers, messenger RNA (mRNA), transfer RNA (tRNA), antisense oligonucleotides, small hairpin RNA (shRNA), microRNA (miRNA), asymmetric interfering RNA (aiRNA), Dicer substrate RNA (dsRNA), ribozymes, peptide RNA (PNA), deoxyribonuclease (DNAzyme), and guide RNA (sgRNA) for gene editing, but this disclosure is not limited thereto. The active ingredient of the composition may be various peptides, protein drugs, protein-nucleic acid constructs, or anionic biopolymer-drug conjugates, such as hyaluronic acid-peptide conjugates, hyaluronic acid-protein conjugates, or antibodies.
[0135] The lipid nanoparticle composition disclosed herein, comprising ionizable lipids, neutral lipids, steroids, polymer-conjugated lipids, etc., can be dissolved in ethanol or a water-miscible solvent to prepare a lipid solution. The active ingredient can be dissolved in citric acid or acetate buffer at pH 4.0 ± 1.0 to prepare an active ingredient solution. Furthermore, the lipid solution and the active ingredient solution can be mixed at a 1:3 volume ratio and a flow rate of approximately 10 mL / min to 15 mL / min using a microfluidic mixing device (Benchtop Nanoassemblr, Precision Nanosystems) to prepare lipid nanoparticles.
[0136] In addition, this disclosure provides compositions for drug delivery comprising a lipid nanoparticle composition and a preventive or therapeutic agent.
[0137] Compositions for drug delivery can be administered to mammals, including humans, via various routes, including parenteral administration. Parenteral administration can be intravenous, subcutaneous, intraperitoneal, or topical, and the dosage can vary depending on the patient's condition and weight, disease severity, drug formulation, route of administration, and timing, but those skilled in the art can make appropriate selections. When formulating compositions for drug delivery according to embodiments, common diluents or excipients can be used, such as fillers, expanders, lyophilizers, binders, wetting agents, disintegrants, and surfactants.
[0138] Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. As non-aqueous solvents and suspensions, propylene glycol, polyethylene glycol, vegetable oils (such as olive oil), and injectable esters (such as ethyl oleate) can be used. As a base for suppositories, Witepsol, polyethylene glycol (macrogol), Tween 61, cocoa butter, lauryl acetate, glycerin, and gelatin can be used.
[0139] The drug delivery compositions disclosed herein can be administered in a pharmaceutically effective amount comprising a preventative or therapeutic agent. The effective dose level of the preventative or therapeutic agent can be determined based on factors including: the type and severity of the patient's disease, drug activity, drug sensitivity, timing of administration, route of administration and excretion rate, treatment duration, concomitant drugs, and other factors known in the pharmaceutical field. The compositions according to the embodiments can be administered as a single therapeutic agent or in combination with other therapeutic agents; they can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered once or repeatedly. Considering all of the above factors, it is important that the administered dose achieves the maximum effect without side effects at the minimum amount, and that such an amount can be readily determined by those skilled in the art. For example, the composition can be administered at doses of 0.001 mg / kg to 10 mg / kg, 0.01 mg / kg to 5 mg / kg, or 0.1 mg / kg to 1 mg / kg.
[0140] Example
[0141] The present disclosure will be described in detail below with reference to embodiments to aid in understanding the present disclosure. However, the following embodiments are merely illustrative of the content of the present disclosure, and the scope of the present disclosure is not limited to the following embodiments. The embodiments of the present disclosure are provided to explain the present disclosure more completely to those skilled in the art.
[0142] <Example 1> Preparation of the compound
[0143] 1-1. Preparation of Compound 1
[0144] Compound 1 was prepared according to reaction scheme 1 below.
[0145] [Reaction Scheme 1]
[0146]
[0147] Specifically, compound 1-a (1.57 g, 10.0 mmol) was dissolved in dichloromethane (29 mL, hereinafter referred to as DCM) at room temperature. Compound 1-b (4.16 g, 10.0 mmol), 4-dimethylaminopyridine (122 mg, 1.00 mmol, hereinafter referred to as DMAP), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (2.88 g, 15.0 mmol, hereinafter referred to as EDCI) were added to the solution, and the mixture was stirred at room temperature for 16 hours. Purified water (29 mL) was added, the mixture was stirred, and allowed to stand. The organic layer was separated, dried with sodium sulfate (hereinafter referred to as Na2SO4), filtered, and the filtrate was purified by column chromatography [methanol (hereinafter referred to as MeOH):DCM = 0:10 → 1:9] to obtain compound 1-c. Compound 1-c (3.56 g, 6.42 mmol) was dissolved in DCM (18 mL) at room temperature. Trifluoroacetic acid (18 mL, hereinafter referred to as TFA) was slowly added to the solution, and the mixture was stirred at room temperature for 3 hours. The solution was then concentrated under reduced pressure and azeotropically concentrated with DCM 4 to 5 times to obtain compound 1-d. Compound 1-d (1.07 g, 2.14 mmol) was dissolved in N-methyl-2-pyrrolidone (32 mL, hereinafter referred to as NMP) at room temperature. Compound 1-e (2.68 g, 17.2 mmol), DMAP (3.14 g, 25.7 mmol), and EDCI (4.93 g, 25.7 mmol) were added to the solution, and the external temperature was raised to 40 °C. The mixture was then stirred for 16 hours. Add purified water (32 mL), extract the mixture with methyl tert-butyl ether (32 mL, MTBE), wash with saturated sodium chloride aqueous solution (32 mL × 2 times, hereinafter referred to as brine), dry with Na2SO4, filter, concentrate under reduced pressure; then dissolve in 10 mL of DCM and perform column purification (MeOH : DCM = 0 : 10 → 1 : 9) to give compound 1.
[0148]
[0149] 1-2. Preparation of Compound 3
[0150] Compound 3 was prepared according to reaction scheme 2 below.
[0151] [Reaction Scheme 2]
[0152]
[0153] Compound 3-a (831 mg, 2.00 mmol) was dissolved in diethyl ether (42 mL, hereinafter referred to as Et2O) at room temperature. Triethylamine (697 μL, hereinafter referred to as TEA) and triphosgene (386 mg, 1.30 mmol) were added, and the mixture was stirred under a nitrogen atmosphere for 2 hours to prepare compound 3-b. Subsequently, compound 3-c (533 μL, 4.00 mmol) was added, and the mixture was stirred under a nitrogen atmosphere at room temperature for 16 hours. After washing with a saturated sodium bicarbonate solution (42 mL, hereinafter referred to as saturated NaHCO3 aqueous solution), the organic layer was dried over Na2SO4 and concentrated under reduced pressure. It was then dissolved in DCM (10 mL) and purified by column chromatography (MeOH : DCM = 0 : 10 → 2 : 8) to give compound 3-d. Compound 3-d (332 mg, 0.594 mmol) was dissolved in 1,4-dioxane (1.5 mL, hereinafter referred to as dioxane) at room temperature, and 4.0 M hydrochloric acid solution (1.49 mL, 5.91 mmol, in dioxane) was added. The mixture was stirred at room temperature for 16 hours. The mixture was concentrated under reduced pressure and azeotropically concentrated with DCM 4 to 5 times to obtain compound 3-e. Compound 3-e (254 mg, 0.594 mmol) was dissolved in NMP (7.6 mL) at room temperature, and compound 3-f (548 mg, 2.97 mmol), DMAP (333 mg, 2.73 mmol), and EDCI (570 mg, 2.97 mmol) were added. The temperature was raised to 45 °C, and the mixture was stirred for 16 hours. The mixture was extracted with purified water (7.6 mL) and MTBE (7.6 mL), washed with brine (7.6 mL × 2 times), dried with Na2SO4, filtered, concentrated under reduced pressure, then dissolved in DCM (3 mL) and purified by column (MeOH : DCM = 0 : 10 → 1 : 9) to give compound 3.
[0154]
[0155] 1-3. Preparation of Compound 4
[0156] Compound 4 was prepared according to reaction scheme 3 below.
[0157] [Reaction Scheme 3]
[0158]
[0159] Compound 4-a (1.57 g, 10.0 mmol) was dissolved in DCM (29 mL) at room temperature. Compound 4-b (4.16 g, 10.0 mmol), DMAP (122 mg, 1.00 mmol), and EDCI (2.88 g, 15.0 mmol) were added, and the mixture was stirred at room temperature for 16 hours. Purified water (29 mL) was added, the mixture was stirred, and allowed to stand. The organic layer was separated, dried over Na2SO4, filtered, and the filtrate was purified by column chromatography (MeOH : DCM = 0 : 10 → 1 : 9) to obtain compound 4-c. Compound 4-c (3.56 g, 6.42 mmol) was dissolved in DCM (18 mL) at room temperature. TFA (18 mL) was slowly added, and the mixture was stirred at room temperature for 3 hours. The mixture was concentrated under reduced pressure and azeotropically concentrated with DCM 4 to 5 times to obtain compound 4-d. Compound 4-d (400 mg, 0.799 mmol) was dissolved in NMP (12 mL) at room temperature. Compound 4-e (954 mg, 5.18 mmol), DMAP (632 mg, 5.18 mmol), and EDCI (992 mg, 5.18 mmol) were added, and the temperature was raised to 40 °C, followed by stirring for 16 hours. Purified water (12 mL) was added, and the mixture was extracted with MTBE (12 mL), washed with brine (12 mL × 2 times), dried over Na₂SO₄, filtered, concentrated under reduced pressure, dissolved in DCM (10 mL), and purified by column chromatography (MeOH : DCM = 0 : 10 → 1 : 9) to give compound 4.
[0160]
[0161] 1-4. Preparation of Compound 5
[0162] Compound 5 was prepared according to reaction scheme 4 below.
[0163] [Reaction Scheme 4]
[0164]
[0165] Compound 5-a (1.57 g, 10.0 mmol) was dissolved in DCM (29 mL) at room temperature. Compound 5-b (4.16 g, 10.0 mmol), DMAP (122 mg, 1.00 mmol), and EDCI (2.88 g, 15.0 mmol) were added, and the mixture was stirred at room temperature for 16 hours. Purified water (29 mL) was added, the mixture was stirred, and allowed to stand. The organic layer was separated, dried over Na2SO4, filtered, and the filtrate was purified by column chromatography (MeOH : DCM = 0 : 10 → 1 : 9) to obtain compound 5-c. Compound 5-c (3.56 g, 6.42 mmol) was dissolved in DCM (18 mL) at room temperature. TFA (18 mL) was slowly added, and the mixture was stirred at room temperature for 3 hours. The mixture was concentrated under reduced pressure and azeotropically concentrated with DCM 4 to 5 times to obtain compound 5-d. Compound 5-d (400 mg, 0.799 mmol) was dissolved in NMP (12 mL) at room temperature. Compound 5-e (1.10 g, 5.18 mmol), DMAP (632 mg, 5.18 mmol), and EDCI (992 mg, 5.18 mmol) were added, and the temperature was raised to 40 °C and stirred for 16 hours. Purified water (12 mL) was added, and the mixture was extracted with MTBE (12 mL), washed with brine (12 mL × 2 times), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. It was then dissolved in DCM (10 mL) and purified by column chromatography (MeOH : DCM = 0 : 10 → 1 : 9) to give compound 5.
[0166]
[0167] 1-5. Preparation of Compound 6
[0168] Compound 6 was prepared according to reaction scheme 5 below.
[0169] [Reaction Scheme 5]
[0170]
[0171] Compound 6-a (1.57 g, 10.0 mmol) was dissolved in DCM (29 mL) at room temperature. Compound 6-b (4.16 g, 10.0 mmol), DMAP (122 mg, 1.00 mmol), and EDCI (2.88 g, 15.0 mmol) were added, and the mixture was stirred at room temperature for 16 hours. Purified water (29 mL) was added, the mixture was stirred, and allowed to stand. The organic layer was separated, dried over Na2SO4, filtered, and the filtrate was purified by column chromatography (MeOH : DCM = 0 : 10 → 1 : 9) to obtain compound 6-c. Compound 6-c (3.56 g, 6.42 mmol) was dissolved in DCM (18 mL) at room temperature. TFA (18 mL) was slowly added, and the mixture was stirred at room temperature for 3 hours. The mixture was concentrated under reduced pressure and azeotropically concentrated with DCM 4 to 5 times to obtain compound 6-d. Compound 6-d (500 mg, 0.999 mmol) was dissolved in NMP (15 mL) at room temperature. Compound 6-e (1.03 g, 7.99 mmol), DMAP (1.47 g, 12.0 mmol), and EDCI (2.30 g, 12.0 mmol) were added, and the mixture was heated to 40 °C and stirred for 16 hours. Purified water (15 mL) was added, and the mixture was extracted with MTBE (15 mL), washed with brine (15 mL × 2 times), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. It was then dissolved in DCM (10 mL) and purified by column chromatography (MeOH : DCM = 0 : 10 → 1 : 9) to give compound 6.
[0172]
[0173] 1-6. Preparation of Compound 7
[0174] Compound 7 was prepared according to reaction scheme 6 below.
[0175] [Reaction Scheme 6]
[0176]
[0177] Compound 7-a (1.43 g, 10.0 mmol) was dissolved in DCM (29 mL) at room temperature. Compound 7-b (4.16 g, 10.0 mmol), DMAP (122 mg, 1.00 mmol), and EDCI (2.88 g, 15.0 mmol) were added, and the mixture was stirred at room temperature for 16 hours. Purified water (29 mL) was added, the mixture was stirred for 10 minutes, and allowed to stand. The organic layer was separated, dried over Na₂SO₄, filtered, and the solution was purified by column chromatography (methanol: DCM = 0:10 → 1:9) to obtain compound 7-c. Compound 7-c (3.56 g, 6.58 mmol) was dissolved in DCM (18 mL) at room temperature. TFA (18 mL) was slowly added, and the mixture was stirred at room temperature for 3 hours. The solution was concentrated under reduced pressure and azeotropically concentrated with DCM 4 to 5 times to obtain compound 7-d. Compound 7-d (730 mg, 1.50 mmol) was dissolved in NMP (21 mL) at room temperature. Compound 7-e (1.88 g, 12.0 mmol), DMAP (2.20 g, 18.0 mmol), and EDCI (3.45 g, 18.0 mmol) were added, and the temperature was raised to 40 °C and stirred for 16 hours. Purified water (21 mL) was added, and the mixture was extracted with MTBE (21 mL), washed with brine (21 mL × 2 times), dried over Na2SO4, filtered, and concentrated under reduced pressure. It was then dissolved in 10 mL of DCM and purified by column chromatography (MeOH : DCM = 0 : 10 → 1 : 9) to give compound 7.
[0178]
[0179] 1-7. Preparation of Compound 8
[0180] Compound 8 was prepared according to reaction scheme 7 below.
[0181] [Reaction Scheme 7]
[0182]
[0183] Compound 8-a (1.80 g, 10.0 mmol) was dissolved in DCM (36 mL) at room temperature. Compound 8-b (4.16 g, 10.0 mmol), DMAP (122 mg, 1.00 mmol), and EDCI (2.88 g, 15.0 mmol) were added, and the mixture was stirred at room temperature for 16 hours. Purified water (29 mL) was added, the mixture was stirred, and allowed to stand. The organic layer was separated, dried over Na2SO4, filtered, and the solution was purified by column chromatography (MeOH : DCM = 0 :10 → 1 : 9) to obtain compound 8-c. Compound 8-c (4.87 g, 9.01 mmol) was dissolved in DCM (24 mL) at room temperature. TFA (24 mL) was slowly added, and the mixture was stirred at room temperature for 3 hours. The solution was concentrated under reduced pressure and then azeotropically concentrated with DCM to obtain compound 8-d. Compound 8-d (671 mg, 1.43 mmol) was dissolved in NMP (17 mL) at room temperature. Compound 8-e (2.33 g, 14.3 mmol), DMAP (2.62 g, 21.4 mmol), and EDCI (4.11 g, 21.4 mmol) were added, and the temperature was raised to 40 °C and stirred for 16 hours. Purified water (17 mL) was added, and the mixture was extracted with MTBE (17 mL), washed with brine (17 mL × 2 times), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. It was then dissolved in DCM (10 mL) and purified by column chromatography (MeOH : DCM = 0 : 10 → 1 : 9) to give compound 8.
[0184]
[0185] 1-8. Preparation of Compound 14
[0186] Compound 14 was prepared according to the reaction scheme shown in Scheme 8 below.
[0187] [Reaction Scheme 8]
[0188]
[0189] Compound 14-a (157 mg, 1.00 mmol) was dissolved in DCM (3.2 mL) at room temperature. Compound 14-b (416 mg, 1.00 mmol), DMAP (12.2 mg, 0.10 mmol), and EDCI (288 mg, 1.50 mmol) were added, and the mixture was stirred at room temperature for 16 hours. Purified water (3.2 mL) was added, the mixture was stirred, and allowed to stand. The organic layer was separated, dried over Na2SO4, filtered, and the filtrate was purified by column chromatography (MeOH : DCM = 0 : 10 → 1 : 9) to obtain compound 14-c. Compound 14-c (442 mg, 0.797 mmol) was dissolved in DCM (4.4 mL) at room temperature. TFA (4.4 mL) was slowly added, and the mixture was stirred at room temperature for 3 hours. The mixture was concentrated under reduced pressure and azeotropically concentrated with DCM 4 to 5 times to obtain compound 14-d. Compound 14-d (175 mg, 0.414 mmol) was dissolved in NMP (5.3 mL) at room temperature. Compound 14-e (603 mg, 1.45 mmol), DMAP (253 mg, 2.07 mmol), and a solution of 2,4,6-tripropyl-1,3,5,2,4,6-trioxaphosphacyclohexane-2,4,6-trioxide (1.32 g, 2.07 mmol, 50 wt%, in DCM) were added, and the temperature was raised to 100 °C and stirred for 16 hours. Purified water (5.3 mL) was added, and the mixture was extracted with EA (11 mL), washed with brine (5.3 mL × 2 times), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. It was then dissolved in DCM (10 mL) and purified by column chromatography (MeOH : DCM = 0 : 10 → 1 : 9) to give compound 14.
[0190]
[0191] 1-9. Preparation of Compound 18
[0192] Compound 18 was prepared according to reaction scheme 9 below.
[0193] [Reaction Scheme 9]
[0194]
[0195] Compound 18-a (901 mg, 3.42 mmol) was dissolved in DCM (18 mL) at room temperature. Compound 18-b (1.42 g, 3.42 mmol), DMAP (41.8 mg, 0.342 mmol), and EDCI (983 mg, 5.13 mmol) were added, and the mixture was stirred at room temperature for 16 hours. Purified water (18 mL) was added, the mixture was stirred, and allowed to stand. The organic layer was separated, dried over Na2SO4, filtered, and the filtrate was purified by column chromatography (MeOH : DCM = 0 : 10 → 1 : 9) to obtain compound 18-c. Compound 18-c (1.12 g, 1.83 mmol) was dissolved in EA (5 mL) at room temperature. Hydrochloric acid solution (4.34 g, 18.3 mmol, 15.4 wt%, in EA) was added, and the mixture was stirred at room temperature for 16 hours. The mixture was then concentrated under reduced pressure to obtain compound 18-d. Compound 18-d (892 mg, 1.81 mmol) was dissolved in NMP (29 mL) at room temperature. Compound 18-e (2.78 g, 10.8 mmol), DMAP (1.99 g, 16.6 mmol), and EDCI (3.12 g, 16.6 mmol) were added, and the temperature was raised to 85 °C, followed by stirring for 16 hours. After cooling, purified water (29 mL) was added, and the mixture was extracted with EA (58 mL), washed with brine (29 mL × 2 times), dried over Na2SO4, filtered, and concentrated under reduced pressure. It was then dissolved in DCM (10 mL) and purified by column chromatography (MeOH : DCM = 0 : 10 → 1 : 9) to give compound 18-f. Compound 18-f (185 mg, 0.153 mmol) was dissolved in MeOH (3.7 mL) at room temperature, and palladium on carbon catalyst (18.5 mg, 5 wt%) was added. The atmosphere was replaced with hydrogen, and the mixture was stirred for 16 hours. The mixture was filtered through diatomaceous earth, washed with MeOH (3.7 mL), and the resulting filtrate was concentrated under reduced pressure and dried to give compound 18.
[0196]
[0197] <Example 2> Preparation of lipid nanoparticles
[0198] Lipid nanoparticles encapsulating firefly luciferase mRNA (RNAGENE, South Korea) were prepared using the compounds (ionizable lipids) prepared in Example 1 above, dioleoylphosphatidylethanolamine (DOPE) or distearate phosphatidylcholine (DSPC) (neutral lipids), cholesterol (steroids), and PEG 2000-DMG (polymer-conjugated lipids). Ionizable lipids, DOPE / DSPC, cholesterol, and PEG 2000-DMG were mixed at a molar ratio of 50:10:38.5:1.5 (composition A) or 49:10:38.5:2.5 (composition B), and dissolved in ethanol at a concentration of 4.8 mg / mL to prepare a lipid solution. Firefly luciferase mRNA was dissolved in citrate buffer (pH 4.0 ± 1.0) or acetate buffer (pH 5.0 ± 1.0) (composition *) to achieve a mRNA:ionizable lipid weight ratio of 1:16 to prepare an active ingredient solution. Subsequently, lipid nanoparticles were prepared by passing the lipid solution and active ingredient solution through a microfluidic mixer (Benchtop Nanoassemblr, Precision Nanosystems) at a flow rate of approximately 15 mL / min to achieve a lipid solution:active ingredient solution volume ratio of 1:3. The prepared lipid nanoparticles were diluted with Tris buffer containing 8.7% sucrose, dialyzed using dialysis centrifuge tubes to reduce the ethanol content to less than 1%, and prepared to a final mRNA-based concentration of 0.2 mg / mL.
[0199] As a control, lipid nanoparticles encapsulating firefly luciferase mRNA (RNAGENE, South Korea) were prepared using SM-102 ionizable lipid, distearate phosphatidylcholine (DSPC) (neutral lipid), cholesterol (steroid), and DMG-PEG2000 (polymer-conjugated lipid). SM-102, DSPC, cholesterol, and DMG-PEG2000 were prepared in a molar ratio of 50:10:38.5:1.5, consistent with the exemplary use of SpikeVax, and were used as control lipid nanoparticles.
[0200] <Analysis Example 1> Confirmation of lipid nanoparticle size and polydispersity
[0201] The particle size and polydispersity of lipid nanoparticles containing the compounds of Example 1 above were measured. To measure the particle size of the lipid nanoparticles, each lipid nanoparticle was diluted with PBS to a concentration of 1 μg / mL of mRNA in each lipid nanoparticle, and the diameter and polydispersity index (PDI) of the lipid nanoparticles (LNPs) were measured using dynamic light scattering (DLS) on a Malvern Zetasizer Nano (Malvern Instruments, UK).
[0202] As a result, as shown in Table 1, all lipid nanoparticles exhibited a particle size of approximately 140 nm or smaller, and good polydispersity of 0.2 or smaller.
[0203] [Table 1]
[0204]
[0205] <Analysis Example 2> Confirmation of Gene Encapsulation Efficiency
[0206] To confirm the gene encapsulation efficiency of the lipid nanoparticles containing the compounds of Example 1 above, Quant-iT was used. TM RiboGreen TM RNA reagents and kits. Take 5 μL of ribosomal RNA standard (100 μg / mL, in TE buffer) and dilute it with 245 μL of TE buffer or 0.4% Triton-TE buffer to prepare stock solutions for calibration curves. Take 2 μL, 5 μL, 10 μL, 25 μL, and 50 μL of the stock solutions and dilute them with TE buffer or 0.4% Triton-TE buffer to adjust the total volume to 100 μL. Then add Quant-iT... TM RiboGreen TM RNA reagent (100 μL) was mixed and the fluorescence intensity was measured (excitation wavelength 475 nm, emission wavelength 500 nm to 550 nm) to prepare a calibration curve. 5 μL of the nanoparticle liquid prepared in Example 2 above was taken and diluted with 245 μL of TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5, in DEPC-treated water). 50 μL of TE buffer or 2% Triton-TE buffer was added to 50 μL of the diluted nanoparticle liquid, and then incubated at 37 °C for approximately 10 minutes. Subsequently, 40 μL of each incubation solution was placed in a microplate, and 60 μL of TE buffer and 100 μL of Quant-iT were added sequentially. TM RiboGreen TMRNA reagents were mixed, and then fluorescence intensity was measured. The measured fluorescence intensity was applied to a calibration curve to calculate the gene amount in TE buffer (T0) and the gene amount in 2% Triton-TE buffer (T2), and then the gene encapsulation efficiency was calculated using Equation 1 below. The calculated gene encapsulation efficiencies are described in Table 2. As a result, all nanoparticles exhibited good gene encapsulation efficiency.
[0207] [Formula 1]
[0208]
[0209] As a result, as shown in Table 2 below, all compounds exhibited good gene encapsulation efficiency of 85% or higher.
[0210] [Table 2]
[0211]
[0212] <Analysis Example 3> Confirmation of gene delivery efficiency of lipid nanoparticles
[0213] 3-1. Confirmation of intracellular gene delivery efficiency
[0214] To confirm the intracellular gene delivery efficiency of the lipid nanoparticles containing the compounds of Example 1 above, FLuc mRNA (as a reporter gene) was encapsulated in the lipid nanoparticles, and its intracellular expression efficiency was evaluated. Since cellular uptake of the lipid nanoparticles is mediated by the LDL receptor (LDLR, low-density lipoprotein receptor), the HeLa cell line (Korea Cell Bank, Seoul), a human cervical cancer cell line expressing high levels of the LDL receptor on its cell surface, was used. Cells were cultured in MEM (minimum essential medium) containing 10% fetal bovine serum (Gibco, NY, USA) and penicillin / streptomycin (Gibco) at 37°C and 5% CO2. Before treatment with the lipid nanoparticles, HeLa cells were cultured at 2 × 10⁶ cells per well. 4 Cells were cultured at a density of 1,000 cells in 96-well plates and, after stabilization for 16 to 24 hours, were treated with lipid nanoparticles at a concentration of 0.25 μg / mL (based on the encapsulated mRNA).
[0215] To confirm intracellular luciferase expression, after 6 hours of treatment with lipid nanoparticles, the culture medium in each well was removed, washed with PBS, and 100 μL of Glo-Lysis buffer (Promega, WI, USA) was added to lyse the cells for 5 minutes at room temperature. Subsequently, the cell lysis buffer and Steady-Glo...TM 50 μL of the luciferase assay solution (Promega) was added to each well of a white 96-well plate at a 1:1 ratio. The plates were incubated at room temperature for 5 minutes, and the luminescence was detected using a GloMax Discover microplate reader (Promega). A calibration curve was prepared using recombinant luciferase (Promega) as a standard, and the concentration of luciferase protein in the cell lysate (pg / mL) was obtained based on the calibration curve.
[0216] As a result, as shown in Table 3 below, the lipid nanoparticles containing the compound of Example 1 were confirmed to exhibit good intracellular gene delivery efficiency.
[0217] [Table 3]
[0218]
[0219] 3-2. Confirmation of in vivo gene delivery efficiency 1
[0220] To confirm the in vivo gene delivery efficiency of the lipid nanoparticles containing the compound of Example 1 above, the lipid nanoparticles were administered to 7-week-old C57BL / 6 mice via a single intravenous injection at a dose of 1 mg / kg (based on the encapsulated luciferase gene), and the mice were sacrificed and their livers were removed 4 hours later.
[0221] To confirm the expression level of luciferase in liver tissue samples, excised liver tissue was transferred to tubes containing 3 mm metal beads, and 500 μL of Glo-Lysis buffer (Promega) was added to every 50 mg of tissue. The tissue was then homogenized using a bead homogenizer. The homogenate was centrifuged at 1000 × g for 10 minutes, and the supernatant was collected and diluted with Glo-Lysis buffer at an appropriate ratio. Subsequently, 50 μL each of the diluted tissue lysate and Steady-Glo luciferase assay (Promega) solution were transferred at a 1:1 ratio to white 96-well plates and incubated at room temperature for 5 minutes. Luminescence was then detected using a GloMax Discover microplate reader (Promega), and a calibration curve was prepared using recombinant luciferase (Promega) as a standard. The expression level of luciferase in the sample (ng / g tissue) was calculated based on this curve.
[0222] As a result, as shown in Table 4 below, the lipid nanoparticles containing the compounds of Example 1 exhibited high levels of luciferase expression in liver tissue after intravenous injection, confirming their function as gene vectors and demonstrating excellent in vivo delivery efficiency upon systemic administration. Furthermore, in in vivo tests, composition B exhibited similar or higher delivery efficiency to composition A.
[0223] [Table 4]
[0224]
[0225] 3-3. Confirmation of in vivo gene delivery efficiency 2
[0226] To confirm the in vivo gene delivery efficiency of lipid nanoparticles after repeated administration, lipid nanoparticles encapsulating EPO mRNA (TriLink BioTechnologies, CA, USA) were intravenously injected into 7-week-old C57BL / 6 mice at a dose of 0.5 mg / kg (based on gene amount). Six hours after administration, plasma was separated from the collected blood by anticoagulation treatment.
[0227] To confirm the concentration of EPO protein expressed in plasma, analysis was performed using an EPO enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, MN, USA) according to the manufacturer's instructions. More specifically, plasma samples were diluted 1:5000 using the sample diluent provided in the kit, and 100 μL of the assay diluent was added to each well. The diluted sample was then added at a 1:1 ratio, and the mixture was incubated at room temperature for 2 hours. Subsequently, all solution was removed from each well, and 200 μL of the EPO conjugate was added, followed by incubation at room temperature for 2 hours. The wells were then washed four times with 300 μL of wash buffer, and 200 μL of substrate solution was added, followed by a reaction time of 20 minutes. The reaction was terminated with 100 μL of stop solution, and absorbance was measured at 450 nm and 600 nm using a Promega microplate reader. Calibration curves were prepared using the standards provided in the kit, and the EPO protein concentration (ng / mL) for each sample was calculated within the limits specified by the standards.
[0228] As a result, as shown in Table 5 below, after repeated intravenous injections, the lipid nanoparticles containing the compound of Example 1 exhibited higher EPO expression levels in the blood than the lipid nanoparticles containing Lipid5 ionizable lipids used as a control. Furthermore, it was confirmed that, unlike the Lipid5-containing nanoparticles, the lipid nanoparticles containing the compound of Example 1 maintained high EPO expression levels well after repeated administration. Considering that Lipid5 is considered to be a known vector that maintains gene delivery efficacy well after repeated administration, it can be confirmed that the compound of Example 1 possesses properties favorable for repeated administration.
[0229] [Table 5]
[0230]
[0231] The specific portions of this disclosure have been described in detail above, and it will be apparent to those skilled in the art that such detailed description represents only preferred embodiments and does not limit the scope of this disclosure. That is, the essential scope of this disclosure is defined by the appended claims and their equivalents.
Claims
1. A compound selected from compounds represented by Formula 1, pharmaceutically acceptable salts thereof, tautomers thereof, prodrugs thereof, or stereoisomers thereof, wherein, R 1 R 2 R 3 and (R) 4 )-X coordinates around the central carbon: <Formula 1> In Equation 1 above, R 1 R 2 and R 3 Each group is independently selected from branched or straight-chain C6-C30 alkyl, alkenyl, alkynyl, C6-C30 cycloalkyl, aryl, or heteroaryl groups, wherein at one or more carbon positions, three or more carbons away from the central carbon, one or more -CH2- groups are replaced by any one of the following groups: -O-, -CH(OH)-, -C(=O)-, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -OP(=O)(OR 5 )O-, -OC(=S)-, -C(=S)O-, -SC(=O)-, -C(=O)S-, -SC(=S)-, -C(=S)S-, -SC(=O)O-, -SC(=S)O-, -OC(=O)S-, -OC(=S)O-, -S-, -SS-, -NR 5 -、-C(=O)NR 5 -、-NR 5 C(=O)-、-OC(=O)NR 5 -、-NR 5 C(=O)O-、-C(=S)NR 5 -、-NR 5 C(=S)-、-OC(=S)NR 5 -、-NR 5 C(=S)O-、-SC(=O)NR 5 -、-SC(=S)NR 5 -and-NR 5 C(=O)S-, where each R 5 It is independently selected from hydrogen, C1-C20 alkyl, C2-C20 alkenyl, alkynyl, C3-C20 cycloalkyl, aryl or heteroaryl; R 4 Selected from branched or straight-chain C2-C12 alkylene, alkenylene, ynylene, (C6-C12)cycloalkylene, arylene, or heteroarylene groups, wherein one or more -CH2- groups are substituted or not substituted from any one of the group consisting of: -O-, -CH(OH)-, -C(=O)-, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -OP(=O)(OR 5 )O-, -OC(=S)-, -C(=S)O-, -SC(=O)-, -C(=O)S-, -SC(=S)-, -C(=S)S-, -SC(=O)O-, -SC(=S)O-, -OC(=O)S-, -OC(=S)O-, -S-, -SS-, -NR 5 -、-C(=O)NR 5 -、-NR 5 C(=O)-、-OC(=O)NR 5 -、-NR 5 C(=O)O-、-C(=S)NR 5 -、-NR 5 C(=S)-、-OC(=S)NR 5 -、-NR 5 C(=S)O-、-SC(=O)NR 5 -、-SC(=S)NR 5 -and-NR 5 C(=O)S-; X is selected from hydrogen or a chain or cyclic heterogroup containing an ionizable amine, wherein the cyclic heterogroup is substituted with or unsubstituted with a C1-C6 alkyl group, a hydroxyl group, or a hydroxy-C1-C6 alkyl group; and n is selected from 0 or 1.
2. The compound of claim 1, wherein, R 1 R 2 and R 3 Each is independently represented by the following equation 1-A: <Formula 1-A> In Equation 1-A above, L is a (C2-C5) alkylene group; A is selected from the group consisting of the following: -O-, -C(=O)-, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -OC(=S-, -C(=S)O-, -SC(=O-, -C(=O)S-, -SC(=S-, -C(=S)S-, -SC(=O)O-, -OC(=O)S-, -S-, -SS-, -C(=O)NR 5 -、-OC(=O)NR 5 -、-C(=S)NR 5 - and -OC(=S)NR 5 -;and R is selected from branched or straight-chain C4-C25 alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heteroaryl, wherein one or more of its -CH2- groups are substituted or not substituted from any one of the group consisting of -O-, -S- and -SS-.
3. The compound of claim 1, wherein, R 4 Selected from C2-C6 alkylene, alkenylene, or ynylene groups, wherein one or more of its -CH2- groups are substituted or not substituted from any one of the group consisting of: -NR 5 -、-C(=O)NR 5 -、-OC(=O)NR 5 -、-C(=S)NR 5 -、-OC(=S)NR 5 -、-SC(=O)NR 5 - and -SC(=S)NR 5 -, where each R 5 It is independently selected from hydrogen or C1-C6 alkyl.
4. The compound of claim 1, wherein, X is selected from an amino group substituted with one or more C1-C4 alkyl groups; or a cyclic heterogroup selected from the group consisting of piperidine, piperazine, and imidazole, wherein the cyclic heterogroup is substituted with or unsubstituted with C1-C4 alkyl, hydroxyl, or hydroxyC1-C4 alkyl groups.
5. The compound of claim 1, wherein, The compound comprises one or more selected from the group consisting of: (1) Di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(3-(piperidin-1-yl)propamido)pimercate, (2) Di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(5-(dimethylamino)pentamido)pimelic acid ester, (3) Di((Z)-dodec-5-en-1-yl)4-(((4-(dimethylamino)butoxy)carbonyl)amino)-4-(3-oxo-3-(((Z)-tetrate-6-en-1-yl)oxy)propyl)heptanediate, (4) Di((Z)-dodec-5-en-1-yl)4-(3-(((Z)-dodec-5-en-1-yl)oxy)-3-oxopropyl)-4-(3-(piperidin-1-yl)propamido)pimelic acid ester, (5) Di((Z)-tetradec-9-en-1-yl)4-(3-oxo-3-(((Z)-tetradec-9-en-1-yl)oxy)propyl)-4-(3-(piperidin-1-yl)propamido)pimelic acid ester, (6) Di((Z)-oct-3-en-1-yl)4-(3-(((Z)-oct-3-en-1-yl)oxy)-3-oxopropyl)-4-(3-(piperidin-1-yl)propamido)pimercate, (7) Di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(1-methylpiperidin-4-carboxamido)pimercate, (8) Di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(1-methylpiperidin-3-carboxamido)pimercate, (9) Bis(2-(heptylthio)ethyl)4-(3-(2-(heptylthio)ethoxy)-3-oxopropyl)-4-(3-(piperidin-1-yl)propamido)pimercate, (10) Di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(1-(2-hydroxyethyl)piperidin-4-carboxamido)pimercate, (11) Di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(4-(piperidin-1-yl)butamido)pimercate, (12) 4-(3-(piperidin-1-yl)propamido)-4-(3-(((Z)-tetradec-9-enoyl)oxy)propyl)heptane-1,7-diyl(9Z,9'Z)-bis(tetradec-9-enolate), (13) Di((Z)-dec-4-en-1-yl)4-(3-(1H-imidazol-1-yl)propamido)-4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)heptanediate, (14) Bis(3-hexylundecyl)4-(3-((3-hexylundecyl)oxy)-3-oxopropyl)-4-(3-(piperidin-1-yl)propamido)pimercate, (15) Bis(3-hexylundecyl)4-(3-oxo-3-(undecyloxy)propyl)-4-(3-(piperidin-1-yl)propamido)pimercate, (16) Bis(3-hexylundecyl)4-(((3-(dimethylamino)propoxy)carbonyl)amino)-4-(3-(((3-hexylundecyl)oxy)-3-oxopropyl)heptanedioate, (17) Bis(3-hexylundecyl)4-(((3-(diethylamino)propoxy)carbonyl)amino)-4-(3-(((3-hexylundecyl)oxy)-3-oxopropyl)heptanedioate, (18) Bis(3-hexylundecyl)4-(3-((3-hexylundecyl)oxy)-3-oxopropyl)-4-(1-(2-hydroxyethyl)piperidine-4-carboxamido)pimercate, (19) 4-(3-((2-hexyldecanoyl)oxy)propyl)-4-(3-(piperidin-1-yl)propamido)heptane-1,7-dimethylbis(2-hexyldecanoate), (20) Bis(3-hexylundecyl)4-(3-(1H-imidazol-1-yl)propamido)-4-(3-((3-hexylundecyl)oxy)-3-oxopropyl)pimercate, (21) Di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(3-(4-methylpiperazin-1-yl)propamido)pimercate, (22) Di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(piperidin-1-yl)heptadiate, (23) Di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(4-(hydroxymethyl)piperidin-1-yl)pimercate, and (24) Di((Z)-dec-4-en-1-yl)4-(3-(((Z)-dec-4-en-1-yl)oxy)-3-oxopropyl)-4-(4-methylpiperazin-1-yl)pimercate.
6. A lipid nanoparticle composition comprising the compound according to any one of claims 1-5.
7. The lipid nanoparticle composition of claim 6, wherein, The compound is an ionizable lipid.
8. The lipid nanoparticle composition of claim 7, wherein, The composition further comprises one or more lipids selected from the group consisting of neutral lipids, steroids, and polymer-conjugated lipids.
9. The lipid nanoparticle composition of claim 8, wherein, The neutral lipids are phospholipids or glycolipids.
10. The lipid nanoparticle composition of claim 8, wherein, The steroids comprise one or more selected from the group consisting of cholesterol, bile acid derivatives, and bile acid derivatives.
11. The lipid nanoparticle composition of claim 8, wherein, The polymer-conjugated lipid is a polyethylene glycol-modified lipid, which comprises one or more selected from the group consisting of: PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, and PEG-modified dialkylglycerol.
12. The lipid nanoparticle composition of claim 8, wherein, The composition comprises 20 mol% to 65 mol% of ionizable lipids, 2.5 mol% to 30 mol% of neutral lipids, 25 mol% to 60 mol% of steroids, and 0.5 mol% to 5 mol% of polymer-conjugated lipids.
13. The lipid nanoparticle composition of claim 8, wherein, The composition further comprises a preventive or therapeutic agent.
14. The lipid nanoparticle composition of claim 13, wherein, The preventive or therapeutic agent is selected from one or more of the group consisting of: small interfering RNA (siRNA), ribosomal RNA (rRNA), ribonucleic acid (RNA), deoxyribonucleic acid (DNA), complementary deoxyribonucleic acid (cDNA), aptamers, messenger RNA (mRNA), transfer RNA (tRNA), antisense oligonucleotides, small hairpin RNA (shRNA), microRNA (miRNA), asymmetric interfering RNA (aiRNA), Dicer substrate RNA (dsRNA), ribozymes, peptide RNA (PNA), deoxyribonuclease (DNAzyme), guide RNA for gene editing (sgRNA), and mixtures thereof.
15. A composition for drug delivery, said composition comprising the lipid nanoparticle composition according to claim 13.
